Aequus Pharmaceuticals Inc (AQS.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 44 | 250 | 764 | 1,386 | 2,238 |
| Receivables | 2 | 310 | 275 | 297 | 266 |
| Inventories | 69 | 94 | 130 | 156 | 130 |
| Other current assets | 45 | 45 | 45 | 0 | 45 |
| TOTAL | $209 | $903 | $1,282 | $1,880 | $2,826 |
| Non-Current Assets | |||||
| PPE Net | 754 | 789 | 824 | 179 | 211 |
| Other Non-Current Assets | 0 | 0 | 567 | 529 | 509 |
| TOTAL | $754 | $789 | $1,390 | $708 | $720 |
| Total Assets | $963 | $1,691 | $2,673 | $2,588 | $3,546 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,100 | 2,000 | 2,000 | 2,000 | 1,986 |
| Accounts payable and accrued liabilities | 139 | 88 | 117 | 96 | 278 |
| Accrued Expenses | 82 | 200 | 88 | 167 | 168 |
| TOTAL | $2,415 | $2,378 | $2,359 | $2,416 | $2,585 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 29 | 28 | 27 |
| TOTAL | $667 | $694 | $678 | $36 | $69 |
| Total Liabilities | $3,082 | $3,072 | $3,037 | $2,452 | $2,654 |
| Shareholders' Equity | |||||
| Common Shares | 23,991 | 23,991 | 23,991 | 23,991 | 23,991 |
| Retained earnings | -30,464 | -29,720 | -28,699 | -28,198 | -27,426 |
| Other shareholders' equity | 4,353 | 4,349 | 4,344 | 4,343 | 4,327 |
| TOTAL | $-2,120 | $-1,380 | $-364 | $136 | $892 |
| Total Liabilities And Equity | $963 | $1,691 | $2,673 | $2,588 | $3,546 |